VIVO
Price:
$33.97
Market Cap:
$1.49B
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the...[Read more]
Industry
Medical - Diagnostics & Research
IPO Date
1986-07-29
Stock Exchange
NASDAQ
Ticker
VIVO
According to Meridian Bioscience, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 21.09. This represents a change of 525.56% compared to the average of 3.37 of the last 4 quarters.
The mean historical PE Ratio of Meridian Bioscience, Inc. over the last ten years is 22.35. The current 21.09 PE Ratio has changed 9.33% with respect to the historical average. Over the past ten years (40 quarters), VIVO's PE Ratio was at its highest in in the June 2017 quarter at 692.39. The PE Ratio was at its lowest in in the June 2022 quarter at -46.09.
Average
22.35
Median
23.13
Minimum
11.86
Maximum
32.68
Discovering the peaks and valleys of Meridian Bioscience, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 175.61%
Maximum Annual PE Ratio = 32.68
Minimum Annual Increase = -36.98%
Minimum Annual PE Ratio = 11.86
Year | PE Ratio | Change |
---|---|---|
2022 | 32.68 | 175.61% |
2021 | 11.86 | -25.29% |
2020 | 15.87 | -4.94% |
2019 | 16.70 | -36.98% |
2018 | 26.50 | -5.32% |
2017 | 27.99 | 11.30% |
2016 | 25.14 | 25.44% |
2015 | 20.04 | -5.04% |
2014 | 21.11 | -17.60% |
2013 | 25.62 | 9.81% |
The current PE Ratio of Meridian Bioscience, Inc. (VIVO) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
20.14
5-year avg
20.72
10-year avg
22.35
Meridian Bioscience, Inc.’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Meridian Bioscience, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Meridian Bioscience, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Meridian Bioscience, Inc.'s PE Ratio?
How is the PE Ratio calculated for Meridian Bioscience, Inc. (VIVO)?
What is the highest PE Ratio for Meridian Bioscience, Inc. (VIVO)?
What is the 3-year average PE Ratio for Meridian Bioscience, Inc. (VIVO)?
What is the 5-year average PE Ratio for Meridian Bioscience, Inc. (VIVO)?
How does the current PE Ratio for Meridian Bioscience, Inc. (VIVO) compare to its historical average?